Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Lenvatinib

Chlorotrianisene

Liver Extracts

Sorafenib

Protein Kinase Inhibitors

Enzyme Inhibitors

The goal of this observational study is to explore the role of prediction of microvascular invasion by radiomics based on pre-treatment magnetic resonance imaging for guiding treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma.

Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma

Prediction of Microvascular Invasion by Radiomics Based on Pre-treatment Magnetic Resonance Imaging (MRI) for Guiding Treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B Hepatocellular Carcinoma (HCC): A Prospective Cohort Study

OS was defined as the interval from the date of enrollment to the date of death due to any cause or last follow-up.

PFS was defined as the interval from the date of enrollment to the date of disease progression or the date of death due to any cause or last follow-up, whichever occurred first.

Assessed by enhanced CT or MR at baseline, every 6 weeks after treatment initiation, using RECIST 1.1 The assessment of tumor response was performed independently by two experienced radiologists who were blinded to the patient's clinical information, and any inconsistent assessment results were resolved by further consensus.

The severity of adverse events will be graded according to Common Terminology Criteria for Adverse Events (CTCAE v5.0) .

Sun Yat-sen University

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma	NCT05889949	Radiomics Hepatocellular ... Transcatheter A... Microvascular I... Multi-kinase In...	Sorafenib Lenvatinib	18 Years - 75 Years	Sun Yat-sen University
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma	NCT05889949	Radiomics Hepatocellular ... Transcatheter A... Microvascular I... Multi-kinase In...	Sorafenib Lenvatinib	18 Years - 75 Years	Sun Yat-sen University

Spots Global Cancer Trial Database for microvascular invasion (mvi)